Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hemicrania continua responsive to verapamil.

Yusuf A Rajabally1, Saiju Jacob

  • 1Department of Neurology, University Hospitals of Leicester Royal Infirmary, United Kingdom.

Headache
|August 20, 2005
PubMed
Summary

Hemicrania continua, a rare headache, usually responds to indomethacin. This study found verapamil effective in a patient resistant to indomethacin, offering a new treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Electrophysiology of Disease Remission in Chronic Inflammatory Demyelinating Polyneuropathy.

European journal of neurology·2026
Same author

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology·2026
Same author

ChatGPT in the diagnosis and management of complex polyneuropathies: comparative analysis with neurologists using real-world cases.

NPJ digital medicine·2026
Same author

Authors response: other autoimmune disorders in chronic immune-mediated neuropathies: why trying to find out does matter.

Expert review of clinical immunology·2026
Same author

Raw, centile and individualised minimal clinically important differences for the MMN-Rasch-built Overall Disability Scale<sup>©</sup> in the monitoring of multifocal motor neuropathy.

Journal of neurology·2026
Same author

Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Hemicrania continua (HC) is a rare, continuous headache syndrome.
  • Indomethacin is the typical first-line treatment for HC.
  • Treatment resistance to indomethacin necessitates exploring alternative therapies.

Observation:

  • A patient with HC initially responded well to indomethacin.
  • The patient's response to indomethacin diminished over time.
  • This patient then received verapamil for their persistent headache.

Findings:

  • The patient with HC experienced a remarkable response to verapamil.
  • Verapamil demonstrated significant efficacy in managing HC symptoms.
  • This suggests verapamil as a viable alternative for indomethacin-resistant HC.

Implications:

  • Verapamil may be a valuable therapeutic option for patients with Hemicrania continua.
  • This finding expands treatment possibilities for refractory HC cases.
  • Further research is warranted to confirm verapamil's role in HC management.

Related Experiment Videos